CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW (USD $)	9 Months Ended
	Dec. 31, 2011		Dec. 31, 2010
Cash Flows From Operating Activities:
Net income	$ 2,078,782	[1]	$ 6,160,220
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,693,018	[1]	463,077
Issue of common shares as compensation			19,760
Changes in operating assets and liabilities:
Inventory	(2,424,798)	[1]	197,645
Advance to suppliers		[1]
Other receivable from related parties		[1]
Accounts payable			(2,299,928)
Customer deposit		[1]
Taxes payable	(248,678)	[1]	278,575
Accrued expenses and other payables	7,620,588	[1]	43,005
Net cash provided by (used in) operating activities	10,718,912	[1]	4,862,354
Cash flows from investing activities:
Addition to plant and equipment	(14,704,423)	[1]	(563,183)
Loan repaid from (provided to) related party		[1]
Prepayment/deposit to Jining Tianruitong for purchasing of drug patents	15,534,631	[1]	(15,354,102)
Net cash provided by (used in) investing activities	830,208	[1]	(15,917,285)
Effect of exchange rate changes on cash and cash equivalents	847,926	[1]	1,046,836
Net increase (decrease) in cash and cash equivalents	12,397,046	[1]	(10,008,095)
Cash and cash equivalents at beginning of period	6,046,804	[1]	11,911,933
Cash and cash equivalents at ending of period	18,443,850	[1]	1,903,839
Cash paid during the periods for:
Interest		[1]
Income taxes	$ 2,178,687	[1]	$ 2,144,058

[1] restated.